HIV treatment sales boost profit at Gilead
The sales of a HIV treatment last year contributed to a sharp increase in pre-tax profits at the main Irish arm of pharma giant Gilead to $55.1m (€41.6m) after revenues topped $2.75bn, writes Gordon Deegan.
The US firm produces Atripla at its Cork plant for HIV and AIDS patients. It provides a combination of three medicines in a single daily pill.
Gilead is the world's largest maker of HIV drugs and last year its worldwide sales of Atripla totalled $2.9bn.
Gilead Sciences, at the IDA Business and Technology Park at Carrigtohill, also produces the Single Tablet Regimen (STR) for HIV patients, called Eviplera.
Accounts show that revenues at the firm increased by 11pc from $2.47bn to $2.7bn, with pre-tax profits increasing from $1.7m to $55.1m.